A new survey has found that the use of AI and real-world data (RWD) is on the rise across the biopharma industry, but hurdles remain.

While genomics is best known for its role advancing precision medicine, MGI Tech has pioneered a new use case in enviromental sustainability.

UNAIDS report warns the US funding collapse could risk millions of new infections and deaths unless countries transform their HIV responses.

Sanofi is sponsoring the event for the second year in a row, which brings together 1,000 transplant recipients and live donors to compete.

A report has found that while many in the UK live with rare diseases, systemic failures continue to restrict progress in treatment.

Explore the latest technology that is changing the pharma industry, and discover how these innovations could solve key health challenges.

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round up.

Rising one place to number one overall, the British drugmaker has overtaken the NHS as the preferred destination for these graduates.

Stefan Oelrich has been newly elected President of the EFPIA, as new leadership calls for action to restore Europe’s global leadership in pharma innovation.

The body is eliminating of Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed CAR T-cell therapies.

Ascroft brings more than 30 years of industry experience, including senior roles at Takeda Pharmaceuticals.

The US plans to stop its financial contributions to Gavi, the Vaccine Alliance, marking an end to an over 20-year partnership.

The survey found that, while 57% of patients support the use of AI in the examination room, they are less enthusiastic about diagnostics.

The FDA has launched an immediate review of clinical trials involving the export of American patients’ living cells to China and other “hostile countries”.

A UK project has received a £1.8m to transform how medicines are made, aiming to make drug manufacturing faster, cleaner and more responsive.

The UK government has set out a 10 Year Health Plan, promising to transform clinical trials and make the UK a scientific superpower.

A £300m bond has been issued by the International Finance Facility for Immunisation to fund vaccine programmes in lower-income countries.

New Ipsos data shows that while 58% of UK adults are willing to join clinical trials, this drops to 41% among ethnic minority adults.

The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.

According to new research from the ABPI, pharma companies need to modernise their outreach strategies.

Vantive has announced the five-year, major investment to expand its R&D and manufacturing capabilities.

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

The King’s Fund in the UK has released an updated explainer on the availability of new medicines in the UK’s NHS.

The Paris biotech aims to improve biologic drugs by mastering glycan control, aiming for safer, more effective therapies.

Catch up on May’s key pharma news, research updates and policy shifts.

BioNTech is set to invest up to £1bn in the UK over the next decade, establishing new R&D and AI hubs.

Experts have pointed to the climate crisis as a potential trigger of the West Nile Virus finding.

Dr Tedros sets out WHO’s next steps on pandemic preparedness, climate action and AMR during the 78th World Health Assembly in Geneva.

Colorectal cancer now has the most real-world data, but Phesi warns clinical trials are lagging behind.

WHAM’s Innovator’s Circle unites top funds to address the women’s health investment gap.

Trump’s “most-favoured nation” drug pricing plan shakes pharma markets, sparking losses for US and EU firms.

The initiative is set to revolutionise healthcare delivery and agricultural exports in low- and middle-income countries.

Gallman takes on the role of EVP, General Counsel and Chief Policy Officer, following Sandra Leung’s retirement after 33 years.

From new scientific data-sharing initiatives to US drug tariffs, May brought a range of major news to the pharma landscape.

Eli Lilly joins forces with Alchemab in a deal worth $415m, expanding its neuroscience pipeline with a novel candidate.

Generation Gold Standard is a universal vaccine platform targeting influenza, coronaviruses and future pandemics.

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor to its renal pipeline.

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways to improve.

Ireland has launched its first national clinical genomics study in paediatric oncology.

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies.

US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.

FluidForm Bio’s 3D bioprinting tech keeps lab-grown cells alive five times deeper using vascular-like gelatin scaffolds.

The UK government has formally signed into law new clinical trial regulations, designed to modernise operations across the country.

CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.

The UK government has announced a significant new initiative to accelerate drug discovery and improve patient care in the country.  

Pharma must balance creativity with transparency to rebuild trust in 2025. VML Health’s report reveals key trends shaping expectations.

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.

Discover the latest pharma innovations, from needle-free vaccines to NHS data access and interactive case studies in medical education.

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

A new study is challenging the belief that dementia is incompatible with modern work environments, with AI helping employees stay in work.

The biopharmaceutical industry’s return on investment in innovation is increasing, but R&D costs are rising, according to a new Deloitte report.

The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

AstraZeneca has announced a $1bn agreement to acquire EsoBiotec, a Belgian biotech firm pioneering in vivo cell therapies.

The NICE has approved the first daily oral treatment for endometriosis symptoms for use within the NHS in England.

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing oncology therapies.

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to the fore.

The UK must increase investment in innovative medicines and vaccines if it is to deliver on the NHS 10-Year Plan and drive economic growth.

The Trump administration is set to cut a total of $60bn in US assistance worldwide, signalling a major shift in health policy.

The company’s investment will expand its US manufacturing footprint and is the largest investment of its kind in history.

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.

The FDA has granted priority review to zongertinib for non-small cell lung cancer (NSCLC).

A new cross-industry report is calling for the UK’s NHS to design its health data infrastructure to meet the needs of pharma researchers.

A new at-home genetic test that assesses the risk of developing coeliac disease has received approval from US regulators.

Robert F. Kennedy Jr has been confirmed as the US Secretary of Health and Human Services following a 52-48 Senate vote.

A new survey from the ABPI has revealed a surge in apprenticeships, placements and global research collaborations in the UK pharma space.

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone Life Sciences.

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked effective options.

Two companies have come together to enhance the way imaging technology is used to assess treatment responses in progressive pulmonary fibrosis.

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the MHRA.

Marco Rubio has authorised an “Emergency Humanitarian Waiver” that ensures continued access to HIV treatment funded by the US.

The World Health Organization has responded to the US government’s freezing of HIV funding as part of a broader pause in foreign aid.

Catch up on January’s top pharma news, from major industry deals and cutting-edge medical innovations to advancements in women’s health.

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

According to new findings by the HBA and FemTechnology, there are significant systemic challenges and unmet needs in women’s healthcare

Takeda is serving as the Industry Lead in the newly launched INTERCEPT project – a multinational collaboration to identify predictive biomarkers for Crohn’s Disease.

The Healthcare Businesswomen’s Association (HBA) has announced its 2025 winners as Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US.

The company’s microbot technology holds huge potential for exploring and delivering treatments to the brain.

The European pharma sector is on the brink of regulatory and operational updates with new papers from pharmaceutical associations 

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe and Japan. 

Micron Biomedical, an Atlanta-based life sciences company, has received funding for its technology that could improve vaccine access.

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

WuXi Biologics sells its vaccine production facility in Ireland to Merck & Co for $500m in the wake of changing regulation in the US.

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Novartis’ Phase III study has demonstrated significant improvement in motor function in children and young adults with spinal muscular atrophy

Discover the latest examples of how pharma and its partners are working together to develop technology to solve key industry challenges.

Catch up on all the latest pharmaceutical industry news from the past month, from breakthroughs in gene therapy to promising drug approvals and more.

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep disorder.

Tessera Therapeutics has announced a partnership with the Bill & Melinda Gates Foundation, securing funding of up to $50m.

A new report by the Office of Health Economics (OHE), commissioned by Pfizer, reveals that respiratory infections can be bad for business.

The drug has received a nod from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Dr Dietmar Berger is set to join Gilead Sciences as Chief Medical Officer on 2 January 2025 – succeeding Dr Merdad Parsey.

The UK is regaining its position as a global hub for industry clinical trials, according to the ABPI, but challenges remain in the space.

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory multiple myeloma.

Amgen is investing $1bn to build a second drug substance manufacturing facility in Holly Springs, North Carolina – increasing the company’s total planned investment in the region to more than $1.5bn.

In a victory for people with sickle cell disease, the US government has announced a major step towards improving access to treatment.

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new breakthroughs and more.

As the MHRA begins a new chapter, the ABPI has published a report outlining the importance of regulatory excellence in the UK.

The Phase 3 PANOVA-3 trial has shown that adding Tumor Treating Fields therapy to standard chemotherapy improved survival in patients.